tetano
Editor, Senior Moderator
Chest
. 2020 Dec 11;S0012-3692(20)35352-6.
doi: 10.1016/j.chest.2020.11.050. Online ahead of print.
Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype
Hui Chen[SUP] 1 [/SUP], Jianfeng Xie[SUP] 2 [/SUP], Nan Su[SUP] 1 [/SUP], Jun Wang[SUP] 3 [/SUP], Qin Sun[SUP] 2 [/SUP], Shusheng Li[SUP] 4 [/SUP], Jun Jin[SUP] 1 [/SUP], Jing Zhou[SUP] 5 [/SUP], Min Mo[SUP] 2 [/SUP], Yao Wei[SUP] 1 [/SUP], Yali Chao[SUP] 6 [/SUP], Weiwei Hu[SUP] 6 [/SUP], Bin Du[SUP] 7 [/SUP], Haibo Qiu[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Corticosteroid therapy is commonly used in patients with coronavirus disease 2019 (COVID-19), while its impact on outcomes and which patients could benefit from corticosteroid therapy are uncertain.
Research question: Whether clinical phenotypes of COVID-19 were associated with differential response to corticosteroid therapy.
Study design and methods: Critically ill patients with COVID-19 from Tongji hospital between Jan 2020 and Feb 2020 were included, and the main exposure of interest was the administration of intravenous corticosteroids. The primary outcome was 28-day mortality. Marginal structural modeling was used to account for baseline and time-dependent confounders. An unsupervised machine learning approach was carried out to identify phenotypes of COVID-19.
Results: A total of 428 patients were included, and 280/428 (65.4%) patients received corticosteroid therapy. The 28-day mortality was significantly higher in patients who received corticosteroid therapy than in those who did not (53.9% vs. 19.6%; p<0.0001). After marginal structural modeling, corticosteroid therapy was not significantly associated with 28-day mortality (HR 0.80, 95% CI 0.54-1.18; p=0.26). Our analysis identified two phenotypes of COVID-19, and compared to the hypoinflammatory phenotype, the hyperinflammatory phenotype was characterized by elevated levels of proinflammatory cytokines, higher SOFA scores and higher rates of complications. Corticosteroid therapy was associated with a reduced 28-day mortality (HR 0.45; 95% CI 0.25-0.80; p=0.0062) in patients with hyperinflammatory phenotype.
Interpretation: For critically ill patients with COVID-19, corticosteroid therapy was not associated with 28-day mortality, but the use of corticosteroids showed significant survival benefits in patients with the hyperinflammatory phenotype.
Keywords: COVID-19; Corticosteroid; Phenotype.
. 2020 Dec 11;S0012-3692(20)35352-6.
doi: 10.1016/j.chest.2020.11.050. Online ahead of print.
Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype
Hui Chen[SUP] 1 [/SUP], Jianfeng Xie[SUP] 2 [/SUP], Nan Su[SUP] 1 [/SUP], Jun Wang[SUP] 3 [/SUP], Qin Sun[SUP] 2 [/SUP], Shusheng Li[SUP] 4 [/SUP], Jun Jin[SUP] 1 [/SUP], Jing Zhou[SUP] 5 [/SUP], Min Mo[SUP] 2 [/SUP], Yao Wei[SUP] 1 [/SUP], Yali Chao[SUP] 6 [/SUP], Weiwei Hu[SUP] 6 [/SUP], Bin Du[SUP] 7 [/SUP], Haibo Qiu[SUP] 8 [/SUP]
Affiliations
- PMID: 33316235
- DOI: 10.1016/j.chest.2020.11.050
Abstract
Background: Corticosteroid therapy is commonly used in patients with coronavirus disease 2019 (COVID-19), while its impact on outcomes and which patients could benefit from corticosteroid therapy are uncertain.
Research question: Whether clinical phenotypes of COVID-19 were associated with differential response to corticosteroid therapy.
Study design and methods: Critically ill patients with COVID-19 from Tongji hospital between Jan 2020 and Feb 2020 were included, and the main exposure of interest was the administration of intravenous corticosteroids. The primary outcome was 28-day mortality. Marginal structural modeling was used to account for baseline and time-dependent confounders. An unsupervised machine learning approach was carried out to identify phenotypes of COVID-19.
Results: A total of 428 patients were included, and 280/428 (65.4%) patients received corticosteroid therapy. The 28-day mortality was significantly higher in patients who received corticosteroid therapy than in those who did not (53.9% vs. 19.6%; p<0.0001). After marginal structural modeling, corticosteroid therapy was not significantly associated with 28-day mortality (HR 0.80, 95% CI 0.54-1.18; p=0.26). Our analysis identified two phenotypes of COVID-19, and compared to the hypoinflammatory phenotype, the hyperinflammatory phenotype was characterized by elevated levels of proinflammatory cytokines, higher SOFA scores and higher rates of complications. Corticosteroid therapy was associated with a reduced 28-day mortality (HR 0.45; 95% CI 0.25-0.80; p=0.0062) in patients with hyperinflammatory phenotype.
Interpretation: For critically ill patients with COVID-19, corticosteroid therapy was not associated with 28-day mortality, but the use of corticosteroids showed significant survival benefits in patients with the hyperinflammatory phenotype.
Keywords: COVID-19; Corticosteroid; Phenotype.